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Introduction
Analyzing the causes of phenotypic adaptation and mal-
adaptation represents a central goal in evolutionary biol-
ogy (Williams 1966, 1992). This goal is usually pursued
using organisms and clades well suited to the measure-
ment of fundamental population-genetic processes and
phylogenetic patterns, and experimental testing among
alternative causal hypotheses. It is difﬁcult to conceive of
a species less amenable to the study of adaptive signiﬁ-
cance than humans, because of their long generation
times, low fecundity, regulation of behavior, and physiol-
ogy by hugely complex brains, acceleratingly novel envi-
ronments, and general experimental intractability. Indeed,
studies of human adaptation seldom deploy measure-
ments of phenotypic selection as an analytic approach;
more frequently, comparative methods are utilized, across
human groups, or across primates, to infer the selective
pressures that have mediated evolution along the human
lineage. Neither of these methods – measurement of selec-
tion and comparative analysis – lacks severe limitations
on the rigor of strong-inference hypothesis testing, given
the problematic nature of reconstructing thousands or
millions of years in history from snapshots of present-day
variation and scraps in the fossil record. Demonstrating
the presence and causes of deviation from maladaptation
(Crespi 2000a; Nesse 2005), in the myriad forms of
human disease risk, is even more challenging, because
hypotheses of adaptation and adaptive tradeoff must be
contrasted with hypotheses based on processes, such as
drift, mutation, and gene ﬂow, that can constrain or delay
optimization by selection (Arnold 1992).
The primary goals of medicine are the prevention,
alleviation, or repair of phenotypes that humans con-
sider maladaptive, via well-substantiated therapies. As
such, the uncertainties of most purported evolutionary
insights into human health concerns usually preclude
consideration serious enough to warrant clinical evalua-
tion, and the practice of medicine defaults to the per-
spective of body and mind as organic machines subject
to forms of physical, physiological, and psychological
breakdown (Williams and Nesse 1991; Nesse and Wil-
liams 1994). Understanding how such a machine works
requires deterministic dissection of component parts and
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Abstract
In this review, I describe how evolutionary genomics is uniquely suited to
spearhead advances in understanding human disease risk, owing to the privi-
leged position of genes as fundamental causes of phenotypic variation, and the
ability of population genetic and phylogenetic methods to robustly infer pro-
cesses of natural selection, drift, and mutation from genetic variation at the
levels of family, population, species, and clade. I ﬁrst provide an overview of
models for the origins and maintenance of genetically based disease risk in
humans. I then discuss how analyses of genetic disease risk can be dovetailed
with studies of positive and balancing selection, to evaluate the degree to which
the ‘genes that make us human’ also represent the genes that mediate risk of
polygenic disease. Finally, I present four basic principles for the nascent ﬁeld of
human evolutionary medical genomics, each of which represents a process that
is nonintuitive from a proximate perspective. Joint consideration of these prin-
ciples compels novel forms of interdisciplinary analyses, most notably studies
that (i) analyze tradeoffs at the level of molecular genetics, and (ii) identify
genetic variants that are derived in the human lineage or in speciﬁc popula-
tions, and then compare individuals with derived versus ancestral alleles.
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by delineation of disease states, and therapy development
based on substantiated causes and patterns of deviation
from optimal function.
The blueprints for our human machine reside, or
course, in the genome, and accelerating progress in geno-
mic technology, and deciphering the genomic bases of
disease risks, has put genetics at the forefront of recent
studies in the etiology of polygenic disease. Genes under-
lying disease have, like all other genes, evolved under the
inﬂuence of natural selection and other population
genetic processes. What role, then, should evolutionary
biology play in the design and interpretation of geneti-
cally based studies of disease risk?
In this paper, I describe conceptual frameworks for
integrating two ﬁelds, the genetics of polygenic disease
risk, and the genetic evolution of modern humans, that
have developed in considerable isolation despite their reli-
ance on the same forms of genomic data. I ﬁrst provide
an overview of theory for analyzing and understanding
human polygenic disease risk, and summarize recent
advances that provide the ﬁrst clear pictures of its gen-
ome-scale landscapes of allelic risk effects. Next, I describe
the development and structure of a parallel research
enterprise, elucidation of the ‘genes that make us human’
through studies of positive Darwinian selection along our
lineage. Third, I discuss how these ﬁelds can be dovetailed
to accelerate progress in both endeavors. And ﬁnally, I
present four basic yet nonintuitive principles for the nas-
cent ﬁeld of evolutionary medical genomics, each of
which serves to integrate proximate, mechanistic perspec-
tives with the ultimate evolutionary dynamics of risk
alleles and disease phenotypes, in the origin and diversiﬁ-
cation of modern humans.
The genes that make us sick
Genetically based disease risk poses an apparent paradox,
given that many disorders with notably negative impacts
on survival and reproduction are both relatively common
and highly heritable (Keller and Miller 2006; Blekhman
et al. 2008). A primary motivation of the human genome
project, and projects that characterize genetic variation
across the genome (e.g. Manolio and Collins 2009), has
been the discovery and characterization of disease risk
alleles, to account for heritable risk, infer the causes of
polygenic disease at the levels of development, physiology,
and pathways, and guide strategies for treatment and pre-
vention. Vulnerability to disease mediated by such alleles
is usually construed in terms of mistakes and weaknesses
in construction–de novo and segregating alleles that are
each slightly deleterious, in comparison to simple Mende-
lian diseases of large negative effect.
Ongoing searches for the ‘disease genes’ and ‘risk
alleles’ that underly human dysfunction are conceptually
structured, and empirically focussed, by ﬁve main axes of
genetic disease risk (Altshuler et al. 2008; Manolio et al.
2009):
1 Disease frequency, between vanishingly rare and com-
mon, with high frequencies mediated by genetic factors
that may be dependent on environmental variation;
2 Disease severity, in the context of effects on age-speciﬁc
survival, with earlier-onset and high mortality rates, or
effects on reproduction, indicating more severe;
3 De novo versus segregating variation – how much of
disease risk is attributable to new, necessarily rare muta-
tions, detectable only by comparing affected offspring
with parents, compared to segregating variation, with risk
alleles having successfully passed through at least one gen-
eration;
4 Common versus rare allelic variants. For sites with
segregating variation, are disease risk alleles relatively
common (e.g. with minor alleles at frequencies of 1%, or
5%, or above) or more rare?
5 Penetrant versus nonpenetrant effects of risk alleles.
How likely is someone harboring a risk allele to exhibit
the disease – between 100%, as in some monogenic dis-
eases, and several percent, at the threshold of statistical
estimation that increased risk exists?
These ﬁve axes are inter-related by the expectation that
mutation–selection balance, and purifying selection gener-
ally, will more rapidly remove relatively more highly dele-
terious alleles from populations. As a result, more
common diseases should tend to be less severe, more
likely due to segregating compared to de novo variation,
and less penetrant in the effects of risk alleles. A simple
graphical model showing effects of de novo and segregat-
ing variants is presented in Fig. 1, and the expected
inverse relationship between effect size of a disease risk
allele, and its expected frequency in a population, is
depicted in Fig. 2.
The idea that more common diseases should be medi-
ated by effects from large numbers of common, low-pen-
etrance disease risk alleles was originally framed as the
‘common-disease common-variants’ hypothesis (Reich
and Lander 2001; Pritchard and Cox 2002). This hypothe-
sis has recently become subject to robust tests via the
availability of technology for measuring relatively com-
mon allelic variants across the entire human genome –
so-called GWAS (genome-wide association studies)
(Corvin et al. 2010). A large suite of GWA investigations,
over the past 4 years, has successfully identiﬁed common
risk variants for diseases of high heritability, such as
schizophrenia, cancer and type 2 diabetes (Stratton and
Rahman 2008; Psychiatric GWAS Consortium Coordinat-
ing Committee 2009; Stolerman and Florez 2009; Cazier
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comparable GWA analyses of height (McEvoy and Vis-
scher 2009) and intelligence (Deary et al. 2009), conver-
gently indicate that very large numbers – hundreds,
thousands, or tens of thousands – of relatively common
allelic variants with small effects mediate variation in
polygenic human traits, but cumulatively account for
<50% of estimated heritability (Goldstein 2009; Ku et al.
2010; Yang et al. 2010). The keys of ‘missing’ heritability
may be hiding in any number of places (Weiss 2008;
Manolio et al. 2009), with the street lamps of genomic
technology now shining on rare variants of moderate to
large effect (Fearnhead et al. 2004; Zhao et al. 2007;
Bodmer and Bonilla 2008). Indeed, rare genomic copy
number variants have been identiﬁed as penetrant risk
factors for schizophrenia, autism, and intellectual disabil-
ity, although they appear to account for only a small per-
centage of known risk (Wain et al. 2009).
Under the disease risk paradigms that guide GWA and
rare variant investigations, mutation and purifying selec-
tion are normally considered, either implicitly or explic-
itly, as the primary population genetic and evolutionary
genetic forces that modify the frequencies of disease risk
alleles. But if thousands of alleles modify risk, for exam-
ple, of schizophrenia – are they actually alleles ‘for’ this
condition (Kendler 2005), or might they be better con-
ceived as alleles ‘for’, say, the neurodevelopment of social
cognition? More importantly, must such alleles, for any
common disease, represent slightly malfunctional cogs
in our human machine with respect to its functioning
Figure 1 Polygenic disease risk for a given individual can be depicted as a combination of risk owing to alleles inherited from parents (inherited
polygenic liability), and risk owing to new mutations (de novo germline mutation). Somatic mutation during development is also likely to be
important, but has yet to be studied in detail.
Figure 2 The frequency spectrum of human disease risk alleles includes alleles at all frequencies from rare to common, with effect sizes from
high to low, with the relative importance in risk of different variants yet to be ascertained. From Manolio et al. (2009).
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some contexts?
The primary population-genetic processes that inﬂu-
ence allele frequencies, in addition to mutation and puri-
fying selection against deleterious alleles, or drift, are
forms of positive selection and balancing selection. An
additional, nonexclusive model for the generation and
maintenance of genetic variation underlying polygenic
disease risk, in addition to models based on some mixture
of myriad segregating deleterious variants of small effect
and rare deleterious mutations of larger effect (Fig. 2), is
thus predicated on advantages, now or in the past, from
alleles that inﬂuence such risk (Keller and Miller 2006;
Kryukov et al. 2007). Variation can be maintained under
this model by two main processes, ongoing positive selec-
tion and balancing selection, that can keep risk alleles at
nontrivial frequencies either transiently as selection pro-
ceeds or at more or less stable equilibria. Support for the
model comes from several recent studies that have dem-
onstrated enrichments of positive selection on polygenic
disease genes, compared to other genes, in human
populations (Nielsen et al. 2007; Blekhman et al. 2008;
Lappalainen et al. 2010); similarly, Amato et al. (2009)
demonstrated higher levels of among-population differen-
tiation, which can be indicative of divergent positive
selection, in complex-disease genes than in a set of con-
trol genes.
Several evolutionary genetic hypotheses may plausibly
explain enrichments of positive selection on polygenic
disease genes.
First, common alleles that were advantageous in ances-
tral environments (for example, ‘thrifty’ genes affecting
regulation of metabolism) are deleterious in current envi-
ronments, and derived, formerly-maladapted alleles are
now selected for (Di Rienzo and Hudson 2005; Di Rienzo
2006). This ‘ancestral-susceptibility’ model has been sup-
ported by data from molecular evolutionary, geographic
and physiological analyses of genes involved in risk of
hypertension, type 2 diabetes, and several other common
human diseases (e.g. Di Rienzo and Hudson 2005; Young
et al. 2005; Helgason et al. 2007), and it provides a robust
predictive framework for testing hypotheses on the
dynamics of disease-related alleles. Positive selection in
this context may involve phenotypes that are more or less
ﬁxed in humans, and adaptations because of geographi-
cally varying selective pressures that generate population
differentiation (e.g. Novembre and Di Rienzo 2009; Adey-
emo and Rotimi 2010). In humans, such selection should
be recent, in the past thousands and tens of thousands of
years (Hawks et al. 2007), and should involve strong
selective pressures given that humans originated in equa-
torial Africa but spread worldwide across all climatic and
ecological zones.
Strong, well-replicated patterns of positive selection on
skin pigmentation and lactose tolerance genes represent
paradigmatic examples of local adaptation (e.g. Harris
and Meyer 2006), with additional examples of population
differentiation apparently mediated by selection including
sodium homeostasis (Young et al. 2005), body mass and
shape (Katzmarzyk and Leonard 1998; Wu and Zhang
2010), and metabolic rate (Snodgrass et al. 2005). This
suite of phenotypes subject to population differentiation
and selection corresponds closely to the set of traits dys-
regulated in human metabolic disorders, including hyper-
tension, obesity, dyslipidemia, and type 2 diabetes, that
jointly deﬁne the human ‘metabolic syndrome’. Hancock
et al. (2008) indeed demonstrate strongly-enriched signals
of population differentiation in 82 candidate genes for
common human metabolic disorders, which they inter-
pret primarily in terms of local selection from heat and
cold stress. Selective pressures due to transitions from
hunting and gathering to farming are also expected to
strongly mediate susceptibility to polygenic disease, as
suggested by signals of positive selection on celiac disease
risk alleles (Barreiro and Quintana-Murci 2010), and the
inferred time of origin for a positively-selected allele of
TCF7L2, a gene that underlies risk of type 2 diabetes,
near to the origin of agriculture (Helgason et al. 2007).
The ancestral-susceptibility model is generally con-
ceived to apply to ecological factors, such as climate and
diet, that are subject to selection for unidirectional tran-
sitions, at different scales of environmental variation in
time and space from local to global. This model can,
however, be generalized to other forms of selective pres-
sures that generate evolutionary disequilibria, including
genomic conﬂict situations where antagonistic coevolu-
tion generates more or less constant states of disequilib-
rial change (Crespi 2010a). The primary limitation of
such models is the general lack of direct evidence
regarding the targets and agents of selection – for exam-
ple, do individuals bearing alternative alleles, for genes
that show strong latitudinal allele frequency clines (Han-
cock et al. 2008), differ in both heat or cold tolerance,
and risk of metabolic diseases? For loci showing evi-
dence of genomic conﬂicts, what phenotypes are
selected, and how do they beneﬁt one party at a cost to
the other? The striking among-population differences in
patterns of positive selection, across the genome, shown
by analysis of the human Hapmap data (e.g. Voight
et al. 2006) suggest that local, recent selective pressures
have substantially impacted human phenotypes and risk
of disease. The pervasiveness of temporal and spatial vari-
ation in selective pressures, because of both ecological and
non-ecological factors, also underscores the central impor-
tance of gene by environment interaction effects in the
phenotypic expression and genomic analysis of human
Crespi Evolutionary health
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et al. 2010).
A second genetic process that may help to explain an
enrichment of positive selection on polygenic disease
genes is balancing selection mediated by antagonistic plei-
otropy, or other processes including overdominance or
frequency-dependent selection. Extensive pleiotropy is
well documented as a universal mode of gene action (e.g.
Knight et al. 2006; Barreiro et al. 2008), and a role for
this process in patterns of positive selection and disease
was suggested by Nielsen et al. (2005) in the context of
‘selﬁsh’ mutations of tumor suppressor genes to increased
rates of spermatogenesis that pleiotropically increase risks
of cancer. More generally, under antagonistic pleiotropy,
alleles exert positive effects in one developmental, physio-
logical, of behavioral context, or at one time in the life-
span, that are stronger than, or balanced by, negative
effects, expressed in some other context or later in life
(Keller and Miller 2006; Kryukov et al. 2007), that mani-
fest as risk of disease. Stronger advantages in one selective
situation, such as one tissue or one life stage, can support
stronger deleterious effects. Such deleterious effects are
expected to be selected against (see e.g. Pavard and Met-
calf 2007; Drenos and Kirkwood 2010), especially to the
extent that they occur before reproduction and alloparen-
tal care-giving have largely ceased, they can be dissociated
genetically via recombination, or they can be alleviated by
selection and response at interacting loci. Antagonistically
pleiotropic effects should thus often be evolutionarily
transient.
A more fundamental, long-term form of pleiotropy
involves intrinsic tradeoffs between opposing selective
pressures, based ultimately on the necessity that energy,
time, or molecular processes devoted to one biological
function, such as some aspects of growth, reproduction,
or defense and maintenance, must take away from others
(Roff 2007). Tradeoffs are fundamental to life history the-
ory in evolutionary ecology and can apparently maintain
substantial levels of genetic and phenotypic variation in
such contexts (Roff and Fairbairn 2006; Kruuk et al.
2008). At the levels of genes, proteins and developmen-
tal–physiological pathways, tradeoffs are expected to be
no less pervasive, with alternative allocation of cellular
resources to different functions, and degrees of low versus
high pathway activation, mediating risk of alternative dis-
ease states (e.g. Stearns 2005; Caricasole et al. 2005; van
Heemst et al. 2005; Reddy et al. 2009; Crespi 2010a).
Tradeoffs associated with polygenic disease risk manifest
in several important contexts, including the following: (i)
associations of traits that are expected to be beneﬁcial,
such as higher birth weight, with diseases such as cancer
(e.g. Maehle et al. 2010) that plausibly represent late-life
pleiotropic effects of the favored phenotype; (ii) negative
associations between diseases, such as genetically based
inverse risk alleles, across multiple loci, for different auto-
immune diseases (Sirota et al. 2009; Wang et al. 2010),
and lower rates of cancer in individuals with schizophre-
nia (Dalton et al. 2005; Goldacre et al. 2005; Torrey 2006;
Levav et al. 2007), Parkinson’s disease (West et al. 2005),
and Alzheimer’s (Roe et al. 2010) than in matched con-
trols.
Polymorphisms in several well-studied human genes
provide putative examples of evolutionary genetic trade-
offs involving risk of polygenic disease. For example, (i)
the Arg72Pro polymorphism in the tumor suppressor
gene TP53 engenders lower fertility, but enhanced sur-
vival of individuals with the Pro allele (Ørsted et al. 2007;
Kang et al. 2009); (ii) APOE gene E4 carriers have been
shown in replicated studies to exhibit better verbal skills
than individuals with alleles E3 or E2 when young, but
higher risk of Alzheimer’s and schizophrenia when older
(Xu et al. 2006; Alexander et al. 2007; Akanji et al. 2009);
and (iii) antagonistically pleiotropic, age-related effects of
the Arg16Gly and Gln27Glu polymorphisms of the
ADRB2 gene have been demonstrated for measures of
cognition and age-related disease (Bochdanovits et al.
2009; Cagliani et al. 2009; Kulminski et al. 2010). These
studies suggest that balanced polymorphisms may com-
monly be maintained under life history tradeoffs, with
each allele providing beneﬁts in the context of one com-
ponent of ﬁtness but costs, often expressed as disease, in
the context of another. Such tradeoffs are also recogniz-
able as negative genetic correlations between traits in
quantitative genetic studies (e.g. brain size and gyriﬁca-
tion in humans and baboons; Rogers et al. 2010), and as
negative phenotypic correlations when potentially con-
founding effects are controlled. In contrast to selective
sweeps, which may sometimes focus upon a speciﬁc trait
undergoing adaptive change, balanced polymorphisms are
expected to commonly involve multiple traits and trade-
offs between them. Balancing selection and antagonistic
pleiotropy are commonly dismissed as population genetic
forces that maintain variation across many loci, because
of a perceived lack of evidence, but studies drawing on
human genomic variation have uncovered a large suite of
apparent cases over the past 10 years (Andre ´s et al. 2009;
Table 1).
To the extent that changing environments, positive
selection, antagonistic pleiotropy, and other forms of
selection mediate risk of human disease, as well as gener-
ate and maintain genetic variation in risk, the evolution
of human disease risk becomes inextricably linked with
the evolution of modern humans. Similarly, the accumu-
lation of human-speciﬁc and human-concentrated pheno-
types along our lineage (e.g. Harris and Meyer 2006;
Crespi 2010a) generates novel mutational targets for
Evolutionary health Crespi
296 ª 2010 Blackwell Publishing Ltd 4 (2011) 292–314Table 1. Examples of loci showing evidence for allele maintenance by long-term balancing selection and/or antagonistic pleiotropy, with alleles
that affect medically relevant human phenotypes. HLA-locus genes other than HLA-G and C4B are not included (see Solberg et al. 2008 for these
data). Disease risk alleles and alleles under balancing selection need not coincide. Andre ´s et al. (2009) list results from a genome-wide analysis of
balancing selection.
Gene Physiological function Phenotypes References, comments
ACE Cardiovascular Cardiovascular diseases Cagliani et al. 2010
ADRB2 Catecholamine metabolism Intelligence, autism, age-related
diseases
Bochdanovits et al. 2009; Cagliani
et al. 2009; Kulminski et al. 2010;
antagonistic pleiotropy
APOE Lipoprotein transport Enhanced verbal skills in childhood,
higher risk of Alzheimers,
schizophrenia
Xu et al. 2006; Alexander et al.
2007 Akanji et al. 2009;
antagonistic pleiotropy
APOL1 Cholesterol transport Kidney disease, protection against
trypanosomes
Genovese et al. 2010
AVPR1B Neurohormone HPA regulation, depression Cagliani et al. 2009
BSG, CD55,
CD151,
SLC14A1
Blood group antigens Infectious disease Fumagalli et al. 2009a
CAPN10 Insulin signaling Type 2 diabetes Vander Molen et al. 2005;
Harris et al. 2006
CCR5 Immunity, inﬂammation Resistance to HIV Bamshad et al. 2002
CPB2 Blood coagulation, ﬁbrinolysis,
inﬂammation
Cardiovascular, blood diseases Cagliani et al. 2010
FMO3 Metabolism of xenobiotics Unclear Allerston et al. 2007
FSHB Female reproduction Female fertility Grigorova et al. 2007
G6PD Glucose metabolism Malaria risk and G6PD deﬁciency Verrelli et al. 2002
HBB Hemoglobin chain Malaria, anemia Williams 2006
hCH Reproduction Miscarriage Rull et al. 2008
HLA-G Reproduction Miscarriage Tan et al. 2005
Interleukin genes Immunity Infectious disease, inﬂammatory
diseases
Fumagalli et al. 2009b
IL10 Immunity, inﬂammation Infectious disease, inﬂammatory
diseases
Wilson et al. 2006
KIR locus genes Immunity, inﬂammation Infectious disease Norman et al. 2004; Parham 2008
LMBR1 Limb, skeletal system development Polydactyly He et al. 2008
MEFV Inﬂammatory system Autoinﬂammatory disease Fumagalli et al. 2009c
OAZ3 Polyamine synthesis Male infertility Christensen et al. 2006
Olfactory
Receptors
Olfaction Functional signiﬁcance unclear Alonso et al. 2008
PDYN Neuropeptides Epilepsy, schizophrenia Babbitt et al. 2010
PKDREJ Sperm–egg interaction Fertility? Hamm et al. 2007
PCDH genes Protocadherins; brain development Bipolar disorder Noonan et al. 2003; Pedrosa
et al. 2008
PTC Bitter taste perception Ingestion of bitter, toxic plants? Kim et al. 2004
SDHA Mitochondrial metabolism Leigh’s disease (mitochondrial) Baysal et al. 2007
TLR genes CD14,
others
Immate immunity Infectious disease Ferrer-Admetlla et al. 2008
TP53 pathway
genes
Tumor suppressor, senescence Fertility, survival, cancer risk Kang et al. 2009; antagonistic
pleiotropy
ZAN Fertilization Unclear Gasper and Swanson 2006
Cases involving null alleles
ABO blood
group
Unclear Infectious disease risk? Greenwell 1997; Calafell et al. 2008
C4B Immunity Null alleles inﬂuence survival,
autoimmune disease risk
Brai et al. 1994; Arason et al. 2003
FUT2 Blood antigen synthesis Infectious disease, vitamin
metabolism
Koda et al. 2000; Hazra et al. 2008
Carlsson et al. 2009
GJB2 Gap junction gene Hearing loss, dysentery resistance D’Adamo et al. 2009
LILRA3 Immunity Autoimmune disease risk? Hirayasu et al. 2006
Crespi Evolutionary health
ª 2010 Blackwell Publishing Ltd 4 (2011) 292–314 297human-speciﬁc and human-concentrated disease. How,
then, might the spectrum and genetic causes of human
disease risk be related to the genetic evolution of
humans?
The genes that make us human
In a landmark paper, Clark et al. (2003) performed the
ﬁrst analysis, via comparisons of sequence data from
humans, chimps, and mice, that allowed inference of the
positively-selected genetic changes that have taken place
along the human lineage. A plethora of subsequent stud-
ies, using diverse methods and datasets, has extended and
reﬁned the identiﬁcation and analysis of putatively posi-
tively selected genes and other genomic elements, and
gene expression differences, along the human lineage (e.g.
Kelley and Swanson 2008; Oleksyk et al. 2008; Grossman
et al. 2010; Sholtis and Noonan 2010). The primary out-
come of these studies has been lists of genes, SNPs, genic
regions, and enriched functional categories of gene, statis-
tically inferred as candidates for positive selection – but
virtually no information on causation, targets of pheno-
typic selection, or evolutionary trajectories (Hughes
2007).
For a small set of positively-selected ‘microcephaly’
genes, including ASPM, MCPH1, CENPJ, and
CDK5RAP2, genetic data converges, and causally links,
with data from developmental and medical genetics, phy-
logenetics, and paleontology: humans evolved greatly
enlarged brains in part because of adaptive mutations
across this suite of genes, most of which are involved in
centrosomal function during neural development (e.g.
Cox et al. 2006; Tang 2006; Kaindl et al. 2010). By con-
trast, for virtually all other genes and phenotypes, the
causal nature of associations of positive selection at the
gene level, with adaptation along the human lineage,
remains almost entirely obscure. Part of this problem is
some function of complexity in genotype–phenotype
mapping, because of pervasive pleiotropy and epistasis in
developmental pathways (Weiss 2008). But our ignorance
regarding functional effects of the ‘genes that make us
human’ may also arise, in part, from a ‘genes-up’ view of
the evolutionary process, rather than ‘phenotype-down’ –
how we know selection actually operates.
Evolutionary change along the human lineage can be
depicted as a series of nested and overlapping allele fre-
quency alterations, some of which are undergoing recent
selective sweeps at local or global levels, some of which
have become ﬁxed by positive selection or other pro-
cesses, and some of which involve recent or ongoing
accelerated change in some region, compared to other
primates. Each of these processes and forms of genetic
variation, either within Homo sapiens or between Homo
sapiens and our common ancestor with related species
including chimps, Neanderthals, or other hominins
(Green et al. 2010), can be exploited to infer the pheno-
typic effects of the substitutions, which provides insight
into their potential roles in human phenotypic evolution
and evolved risk of disease.
Selective sweeps and accelerated evolution
Recent selective sweeps provide opportunities for the
most direct tests of correspondence between phenotypic
and genomic adaptation: individuals with the putatively
selected, derived haplotype or allele can be compared to
individuals with ancestral haplotypes or alleles, either for
a single trait (e.g, Mekel-Bobrov et al. 2007) for or a suite
of traits that are hypothesized, based on gene functions,
pathways, and tissue expression patterns, to represent
potential targets of phenotypic selection (e.g. Grossman
et al. 2004). Such studies rely on the rapidly developing
ﬁeld of phenomics – the quantitative analysis of pheno-
typic trait-space variation and covariation with the same
comprehensive rigor as genomes (Houle 2010; Lanktree
et al. 2010). Phenomic analyses coupled with inferences
of selection turn a GWAS on its head, into what might
be called a Phenotype Wide Association Study (PWAS),
to determine the best phenotypic correlates of derived
versus ancestral haplotypes. PWAS represents a logical
extension of a much simpler application of positive selec-
tion data – using signatures of selection to identify puta-
tively functional sites and variants – in the study of
human disease risk (e.g. Ding et al. 2008; Atwal et al.
2009). The relationship of derived versus ancestral allele
status to disease risk should depend upon the contexts
and timing of positive selection: derived alleles may be
expected to engender lower risk if the disease itself (or
its subthreshold effects) represents a selective agent (e.g.
Pavard and Metcalf 2007), or higher risk if disease repre-
sents a byproduct of strong, recent selection on some
other component of survival or reproduction (Crespi
2010a). Most generally, PWA studies across the human
genome can identify joint ongoing trajectories of recent
human genetic and phenotypic evolution and evaluate the
contributions of positive selection, compared to purifying
selection and other processes, in risk of polygenic disease.
Indeed, developmental and physiological phenomic tar-
gets of selection may provide more direct clues to gene
and haplotype functions than do associations with dis-
ease, as they help to specify nonpathological and pleiotro-
pic effects of genetic variation for common alleles.
The so-called human-accelerated regions represent
DNA sequences that have evolved (and may still be evolv-
ing) especially quickly along the human lineage, com-
pared to related lineages (Pollard et al. 2006; Prabhakar
Evolutionary health Crespi
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ongoing selective sweeps (which requires that certain con-
ditions be met), but they can be inferred to exhibit func-
tionality based on their genomic locations or regulatory
features, which can serve to exclude hypotheses of rapid
nonadaptive evolution. Accelerated evolution in the
human lineage is expected to mediate risk of human-spe-
ciﬁc disease, as suggested by apparent associations of
SNPs in the RNA gene HAR1A with auditory hallucina-
tions in schizophrenia (Tolosa et al. 2008).
Fixed differences
Human-speciﬁc, derived alleles can be recognized via
comparisons with related species (e.g. Nahon 2003; Kit-
ano et al. 2004; Prabhakar et al. 2006; Green et al. 2010);
analogously, human populations may also harbor unique,
derived alleles (e.g. Baye et al. 2009). Fixed, human-spe-
ciﬁc alleles at sites that are otherwise highly conserved
across primates are expected to subserve aspects of
human-speciﬁc or human-concentrated phenotypes, such
as the two amino acid substitutions in FOXP2 with effects
on articulation and language via altered expression of a
suite of target genes (Konopka et al. 2009). Analyzing
adaptive functions of ﬁxed differences relies on genotype–
phenotype correlations involving natural mutational vari-
ation, or experimental, effects at the sites or gene of inter-
est. For example, the transcription factor GTF2I shows
evidence of strong upregulation in humans compared to
chimps and other primates (Preuss et al. 2004), and dele-
tion mapping of individuals with Williams syndrome, as
well as mouse models, indicates a role for this gene in
modulating social–behavioral interactions (Dai et al.
2009). Remarkably, this gene also shows genomic
imprinting effects with preferential expression from the
maternal chromosome (Collette et al. 2009), suggesting
selective effects from mother-offspring social interactions
that modulate maternal investment (Haig 2010). These
diverse lines of evidence implicate GTF2I in human social
evolution, and should motivate studies of its human-spe-
ciﬁc transcriptional targets and the social-behavioral
effects of natural variation in expression levels. The degree
to which natural or experimentally induced genetic varia-
tion recapitulates the context within which selection has
acted over evolutionary time must remain more or less
unclear. For humans, the best evidence should come from
genome sequencing of archaic H. sapiens fossil DNA
along our recent lineage, over the last few tens of thou-
sands of years, and from study of genetic changes that
involve bidirectionally altered gene dosages (Crespi et al.
2009).
In principle, human-speciﬁc derived alleles should
underly some proportion of human-speciﬁc or human-
concentrated disease risk (Crespi 2010a), with ancestral
alleles, losses of function, or pleiotropic effects of derived
alleles, associated with higher risk of disease. Such studies
may also usefully consider the roles in disease of human-
speciﬁc genes or isoforms (e.g. Nahon 2003; Kitano et al.
2004), as these may provide more substantial targets than
SNPs or amino acids for both dysregulation and selec-
tion.
Do the genes that make us human also make us
sick?
The relevance to human disease risk of positive Darwin-
ian selection, and balancing selection, along the human
lineage is an empirical problem that can be attacked with
increasing power and precision as advances in genomic
technology proceed. This question can be addressed by
cross-referencing data on the status of haplotypes or
amino acids as selected or derived and ﬁxed in the
human lineage (or in speciﬁc populations), with data
from GWA studies on polygenic disease risk (e.g. Loe-
Mie et al. 2010). Studies of positive selection can indeed
be easily dovetailed with GWAS of disease, given that that
same data – high-density SNP information, or whole-gen-
ome sequences – can be used for both. Answering this
question, however, requires causal scaffolding from genes,
to pathways, to human adaptations, and to risks of
disease, because genetic variation exerts its effects on
phenotypic variation, manifest in adaptation and mal-
adaptation, via highly interactive pathways of develop-
ment and physiology (Weiss 2008; Luo et al. 2010). In the
study of human disease risk, such scaffolds have been built
in two main ways. First, once enough disease risk genes are
identiﬁed, concentration of genes in particular pathways
can be statistically assessed, to ascertain which systems are
most commonly dysregulated in disease, and which can
serve as targets for drug development. Second, ‘intermedi-
ate phenotypes’ or ‘endophenotypes’ (e.g. Prasad and
Keshavan 2008; Tan et al. 2008) – traits that are closely
associated with disease states – represent intermediaries
between genes, pathways, and disease risk, because they
can causally link in both directions; for example, a subset
of idiopathic autism has been associated with large head
size, a suite of autism-related genes and copy number vari-
ants also inﬂuence head size, and several pathways have
been recognized whereby these genes exert their effects
(Crespi and Badcock 2008; Crespi et al. 2010).
In the study of positive selection, concentration of
genes in particular, apparently selected pathways is com-
monly tested. Indeed, some pathways with concentrations
of positive selection, such as NRG1-ERBB4 signaling
(Voight et al. 2006) also appear to be targets of polygenic
disease risk (e.g. in schizophrenia, Banerjee et al. 2010);
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among the strongest overall patterns of positive selection
in humans (e.g. Barreiro and Quintana-Murci 2010),
attesting to the powerful selective role of infectious dis-
eases in human evolution. However, as described above,
the actual phenotypic targets of selection, which ulti-
mately generate the signatures of selection in the genome,
have almost never been investigated through comparing
phenotypes of individuals with selected versus ancestral
haplotypes, or individuals with ﬁxed-derived versus
mutated alleles. Similarly, the suites of traits associated
with alternative genotypes at balanced polymorphisms
have seldom been investigated in detail, despite increasing
evidence from detailed genetic studies that balancing
selection is considerably more pervasive than commonly
presumed.
Three examples may illustrate the potential usefulness
of jointly analyzing positive selection and disease risk.
First, the well-known ‘breast cancer’ gene BRCA1 has
been demonstrated as subject to positive selection in sev-
eral studies (Fleming et al. 2003; Pavlicek et al. 2004), but
more generally, the entire BRCA-FANC pathway in
humans, which orchestrates DNA damage–repair
responses, shows an apparent concentration of positive
selection, with 6 of 13 pathway genes, ATM, BRCA1,
CHEK2, FANCA, FANCE, RAD51, showing evidence of
selective sweeps at 0.05 in one or more populations of
the phase II human HapMap data (Voight et al. 2006);
four other genes show signiﬁcance at the 0.10 level. How
do humans with derived and ancestral haplotypes differ
for these genes? Second, a network that includes eight
interacting schizophrenia-associated genes, recently identi-
ﬁed by GWA studies, shows evidence of a remarkable
concentration of positive selection and human-derived
alleles (Loe-Mie et al. 2010). How do individuals that
vary in their ‘schizophrenia-risk’ haplotypes, and patterns
of pathway activation, differ in affect and cognition? Can
ancestral/derived differences be used to help develop
novel therapies, based on how natural selection has
apparently dealt with disease risks in the past (e.g. Moalic
et al. 2010)?
Associations between the recent genetic evolution of
modern humans, and human genetic disease risks, can be
assessed more or less directly by evaluating the roles in
different forms of disease, and associated phenotypes, for
genes inferred as positively selected in the human lineage.
As a third example, I determined disease risk associations
(both polygenic and monogenic) for genes inferred as
positively selected from two recent analyses: (i) the Com-
posite Multiple Signals test, a new, high-resolution test
for alleles undergoing recent selective sweeps, over the
past few tens of thousands of years (Grossman et al.
2010), and (ii) the tests for selective sweeps deployed by
Green et al. (2010), which use the draft Neanderthal gen-
ome to localize inferred selective signals for the early evo-
lution of Homo sapiens sapiens, on the order of 400 000
to 600 000 years ago with apparent, more recent gene
ﬂow. There was no evidence for concentrations of
increased disease association for selected loci across all
diseases for either data set. However, for the Green et al.
(2010) data set, and for both data sets overall, the
inferred, positively selected genes were signiﬁcantly more
frequently associated with neurological diseases (including
schizophrenia, bipolar disorder, depression, dyslexia, aut-
ism, Alzheimers, Parkinson’s and epilepsy) than were
control genes (Table 2). These results suggest that recent
Table 2. Associations with disease, for genes inferred as positively selected via selective sweeps in Grossman et al. (2010, Table S5) or Green
et al. (2010, Table S37), compared to sets of control genes. For selected genes, only single genes (or haplotypes associated with disease) were
included, to avoid ambiguity regarding which gene was the apparent focus of selection. Disease and phenotype associations were obtained from
PubMed searches (as of 31 May 2010) using gene names. As the goal is to compare selected vs control genes for frequency and nature of disease
association, all associations are included, even if reported in a single study. Control genes were ascertained as the genes closest to 4 Mb from the
focal selected gene, centromeric and telomeric.
Numbers of genes shown, for each category (%)
Grossman et al. 2010
(recent sweeps)
Green et al. 2010 (sweeps
after Neanderthal split)
Selected Control Selected Control
No association with disease 35 (53%) 77 (64%) 42 (59%) 76 (62%)
Association with non-neurological disease 14 (21%) 26 (21%) 10 (15%) 30 (25%)
Association with neurological disease 11 (17%) 12 (10%) 15 (21%) 14 (11%)
Association with other phenotypes 6 (9%) 6 (5%) 4 (6%) 2 (2%) Pooled analyses
Disease vs not disease, selected vs control v
2 = 0.8, P = 0.37 v
2 = 0.01, P = 0.91 v
2 = 0.29, P = 0.59
Neurological disease genes vs other genes v
2 = 1.8, P = 0.18 v
2 = 3.17, P = 0.075 v
2 = 5.08, P = 0.024*
Percent of disease genes neurological v
2 = 1.0, P = 0.31 v
2 = 5.20, P = 0.022* v
2 = 3.94, P = 0.047*
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cognitive–affective phenotypes, with direct implications
for risk of neurological disease. The latter data set (Green
et al. 2010) includes evidence for selection on several
genes that mediate other phenotypes that may have been
important in human evolution since our split with Nean-
derthals, such as craniofacial morphology (the ENPP1,
TRPS1 genes) and the timing of tooth eruption (MSRB3)
and puberty (DLK1). Disease-related, putatively selected
genes represent excellent candidates for detailed phenomic
and deep-sequencing studies, to more clearly infer the
apparent phenotypic targets of selection, their genomic
bases, and how disease risks relate to pleiotropy and
human adaptations.
Principles of human evolutionary disease
genomics
A key beneﬁt from bridging between human medical ge-
nomics and human evolutionary genomics is reciprocal
illumination of answers to two of the major unresolved
questions in biology: how we evolved, and why we fall
victim to cancer, schizophrenia, type 2 diabetes, and a
suite of other polygenic, human-concentrated diseases.
The primary challenges in constructing the required links
are lack of in-depth background knowledge among evolu-
tionary geneticists regarding causes of particular geneti-
cally based diseases, and lack of background among
medical geneticists regarding the nuanced causes of evolu-
tionary processes. The latter can be addressed with four
straightforward, yet nonintuitive, principles of human
evolutionary medical genomics, based within the larger
ﬁeld of evolutionary medicine (Nesse and Stearns 2008;
Stearns and Koella 2008; Gluckman et al. 2011).
Human adaptations and disease risks have evolved
together
Evolution along the human lineage is characterized by a
suite of phenotypic changes including, for example, larger
brain size, more advanced social cognition, more invasive
placentation, continuous female receptivity, lower fertility
per cycle, physical altriciality, neurological precociality
and high levels of subcutaneous fat in infants, shorter in-
terbirth intervals, longer childhood, and a peaked female
age-speciﬁc fecundity distribution, with elongated post-
menopausal lifespan in females (Crespi 2010a; Hawkes
2010). Each of these recently evolved human adaptations
is expected to generate increased opportunity and scope
for maladaptive dysregulation, with forms of disease
reﬂecting human trajectories of evolution (Crespi 2010a).
Evolutionary trajectories of genomic and phenotypic
change can provide guidance concerning mechanisms of
disease because they indicate how genes, genomes and
traits that make up the human ‘machine’ have been mod-
iﬁed and assembled, step by step, via selection and other
processes along the human lineage. For example,
advanced social cognition and emotionality have evolved
along the human lineage via a series of nested genetic
changes involving neurodevelopmental ‘social-brain
genes’, so the genetic regions that have undergone, and
are undergoing, such evolutionary changes should, as
noted above, represent prime candidates in the etiology
of autism and schizophrenia.
Most generally, these considerations suggest that the
global landscape of human polygenic diseases, in terms of
form, prevalence, severity, de novo versus segregating alle-
lic etiology, mediation by common and rare alleles, and
penetrance of alleles, should correspond, in part, to the
landscape of recent human evolutionary genetic and envi-
ronmental changes; for example, metabolic syndrome
phenotypes appear to reﬂect, in part, dysregulated adapta-
tions subsequent to human dispersal from Africa (Han-
cock et al. 2008) as well as more recent dietary changes.
Disease genetic studies of hunter–gatherer and traditional
horticultural human populations can be used to help
parse recent environmental change effects from older
adaptations (e.g. Gurven et al. 2008, 2009).
An important implication of such evolutionary per-
spectives on disease is that some so-called diseases may
represent adaptations that increase reproductive success
but decrease ‘health’, some may represent maladaptation
because of recently altered environments (Nesse and Wil-
liams 1994), some may represent side effects of genomic
conﬂicts (Haig 1993, 2006; Ubeda and Wilkins 2008;
Crespi 2010a,b), and others may represent maladaptive,
genetically based extremes of adaptations (e.g. Nesse
2004a). For example, mental health is often conﬂated
with happiness, yet natural selection is expected to maxi-
mize not happiness, but striving for resources that have
led, over recent evolutionary time, to increased reproduc-
tive success (Nesse 2004b; Nettle 2006). From this per-
spective, depression, or at least its mild manifestations in
low mood, can be considered to subserve adaptive emo-
tional functions that regulate motivation and modulate
seeking of goals (Keller and Nesse 2006). Similarly, a cen-
tral phenotype of bipolar disorder – mania – involves
euphoria, racing thoughts, talkativeness, and high levels
of sociability, mainly focussed around extreme, dysregu-
lated pursuit of two proximately reproductive goals:
money and sex (e.g. Johnson 2005). Does mania repre-
sent, in part, human striving for reproductive success run
amok? Is hypomania (mild mania), in subclinical form, a
behavioral target of selection in humans? Associations of
bipolar disorder with high socioeconomic status (Coryell
et al. 1989), high marks in school (MacCabe et al. 2010),
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hypothesis. Moreover, a recent study has demonstrated a
signiﬁcantly lower genome-wide ‘burden’ of presumably
deleterious copy number deletions in bipolar patients
compared to controls (Grozeva et al. 2010), which con-
trasts markedly with studies showing signiﬁcantly higher
burdens of copy number variants in two conditions,
schizophrenia (ISC 2008; Kirov et al. 2009) and autism
(Sebat et al. 2007), with less-direct links to ﬁtness-related
phenotypes. Such convergent ﬁndings should motivate
studies that evaluate the cognitive, affective, and behav-
ioral effects of bipolar genetic ‘risk’ variants in nonclinical
populations, test for positive selection on such variants,
and measure copy number burdens with regard to other
heritable conditions involving exceptional human perfor-
mance, such as high ‘intelligence’.
Alleles, the primary units of natural selection, mediate
the evolution of adaptation and disease risk via complex
mixtures of conﬂict and cooperation, within and between
loci and individuals
Explanations for adaptation based on the ‘good of the
group’ or species were purged from evolution, ecology,
and behavior in the 1960s and 70s, when it was demon-
strated that alleles are the only entities in the hierarchy of
biological life that persist long enough to have their fre-
quencies adjusted or maintained by selection (Williams
1992; Keller 1999; Crespi 2000b). ‘Good of the species’
arguments persist, however, where one might least expect
them – among geneticists, where the generation of vari-
ants is often seen as beneﬁcial because it facilitates the
efﬁcacy of evolution. This viewpoint is intellectually per-
nicious because it blinds researchers to the processes that
actually drive molecular evolutionary change and to well-
established consequences of gene-level selection, such as
genomic conﬂicts, that mediate a substantial proportion
of human disease risk.
The sequelae to alleles as the primary units of selec-
tion, and consequent genomic conﬂuence and conﬂicts
of interest within and between individuals, are funda-
mental to understanding adaptation and disease in two
central ways. First, from an evolutionary perspective, a
‘gene’ represents a haplotype variant of indeterminate
size, with larger haplotypes more likely to exert greater
phenotypic effects (that may be selected for or against)
but less likely to avoid being broken apart by recombi-
nation. A positively selected haplotype may increase in
frequency as a result of a single base-pair change along
a megabase length, with linked, neutral, or deleterious
variants dragged along until recombination happens to
separate them. This hitch-hiking process has long been
recognized in genetics, but its roles in adaptation and
disease remain virtually unstudied. For example, a small
section of chromosome 15 includes the eye-color gene
OCA2, directly adjacent to the brain receptor gene GAB-
RG3. Strong, recent positive selection has been reported
for a blue-eyed haplotype of OCA2 (McEvoy et al.
2006), a series of studies has demonstrated associations
of blue eyes with timid, inhibited behavior in children
(e.g. Rosenberg and Kagan 1987; Coplan et al. 1998),
and alleles of GABRG3 have been associated with autism
(Menold et al. 2001). Has linkage disequilibrium
between OCA2 and GABRG3, coupled with selection for
blue eyes, generated associations of eye color with per-
sonality traits, autism, or both? Of course, the region of
the human genome with among the strongest signals of
selection, and the highest levels of linkage disequilib-
rium, is perhaps the most important for disease: the
3.6-Mb MHC region on chromosome six.
Second, genomically based conﬂicts are a fundamental
outcome of gene-level selection, because different alleles
at a locus, and alleles at loci with different patterns of
inheritance and different patterns of genetic relatedness to
interactants, can be selected for effects that ‘beneﬁt’ the
focal allele (increase its frequency) even at a replication
cost to other alleles, or a ﬁtness cost to individuals. Geno-
mic conﬂicts come in two main types: (i) intragenomic
(within-genome) conﬂicts include genomic imprinting,
forms of drive (meiotic, meiotic stem cell, gestational,
and centrosomal), sex–chromosomal interactions, and
mitochondrial–nuclear relationships; and (ii) intergenomic
conﬂicts involve competition between categories of indi-
vidual, such as parent–offspring, maternal–fetal, sib–sib,
male–female, female–female and male–male (Burt and
Trivers 2006; Rice et al. 2008; Crespi 2010a). Costs of
genomic conﬂicts may themselves manifest as disease, and
more generally, evolved systems of conﬂict represent
mechanisms that can become dysregulated via one party
(allele, genomic element, or class of individual) ‘winning’
(reaching its optimum, while the other party suffers a fre-
quency or ﬁtness reduction), physiological costliness from
dynamic tug of war (Haig and Graham 1991), new muta-
tional targets from evolved conﬂict systems, and long-
term, ongoing antagonistic coevolution. In each form of
conﬂict, ﬁtness differentials between competing parties
are expected to be extremely strong (as for host–parasite
interactions), also increasing the scope for deleterious
pleiotropic effects of conﬂictually driven allele frequency
change.
Genomic conﬂicts appear to be especially pervasive in
the contexts of competition over reproductive resources
that mediate differential survival and growth, such as
maternal–fetal interactions (Haig 1993, 1996a,b, 1999,
2007), and meiotic and gestational drive (Zollner et al.
2004; Haig 1996a,b, 1997). For example, Haig (1993,
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mary disorders of human reproduction, including infertil-
ity, early pregnancy loss, gestational diabetes, pre-
eclampsia, and intrauterine growth restriction and show
evidence of strong effects from genomic conﬂicts, as well
as human-speciﬁc adaptation. Genomic imprinting effects
in particular appear to play central roles in a suite of dis-
orders including disrupted placentation (Fowden et al.
2006), cancer (Jelinic and Shaw 2007), altered metabolism
of glucose and lipids, key currencies for fetal development
(e.g. Chen et al. 2005; Haig 2008), and neurodevelop-
mental disorders (Crespi 2008; Crespi and Badcock 2008),
as deleterious side effects of their roles in orchestrating
prenatal and postnatal growth, and neurodevelopment
(Ubeda and Wilkins 2008; Das et al. 2009; Crespi 2010b).
Indeed, Kong et al. (2009) estimate from pedigree-based
GWA data that 13–15% of the genetic risk for type 2 dia-
betes involves parent of origin effects (see also Voight
et al. 2010), and some of the most penetrant and well-
established risk factors for schizophrenia and autism
involve imprinted genes (Crespi 2008; Crespi and
Badcock 2008; Ludwig et al. 2009; Pun et al. 2010). The
incidence of positive selection on imprinted compared to
nonimprinted genes has yet to be systematically evaluated,
but two of the genic regions inferred as positively selected
in Grossman et al. (2010) are imprinted (see also Lo et al.
2007). Positive selection has also been reported in the
imprinted genes C15orf2 (Wawrzik et al. 2010) and
KLF14 (Parker-Katiraee et al. 2007), and alleles of this lat-
ter gene show strong links to carcinoma (Stacey et al.
2009) and plasma lipid concentration (Chasman et al.
2009) in recent GWA studies.
Some direct applications of genomic conﬂict theory to
health practitioners include: (i) disease-related maternal
or fetal phenotypes expressed in pregnancies that may
be either conditionally adaptive responses of mothers or
fetuses to developmental perturbations, or deleterious
manifestations of pathology; in the former case, treat-
ments to alleviate symptoms are expected to make mat-
ters worse for one or both parties (Haig 2004, 2007);
(ii) diseases in offspring owing to noninherited maternal
haplotypes that negatively impact fetal development
(Haig 1996a,b, 1997; Johnson 2003); (iii) the importance
of family-based studies, which can be used to detect
parent of origin, imprinting effects that case–control
analyses cannot; and (iv) recognition of novel, funda-
mental causes of psychological conditions, such as high
levels of insecure attachment (psychosocial bonding) in
childhood, because of parent–offspring conﬂicts com-
monly resolved in the parent’s favor, that can reduce
psychological well-being throughout later life (Crespi
2010b; see also Wells 2003). More generally, conﬂicts
will usually not be observed unless explicitly sought, in
part because they are invisible, senseless, or wasteful
from the perspective of body and mind as coherent,
unitary machines.
Strong natural selection early in life, from infectious
diseases and interacting effects of nutritional status, is
expected to sustain substantial negative effects on health
in later life
Survivorship curves for poor, third-world human popula-
tions, and hunter–gatherer populations, drop precipi-
tously from birth, with about 50% of children lost before
the ages of 10–15 (Gurven et al. 2007; May 2007; see also
Metcalf and Pavard 2007). Most of this mortality occurs
in infancy, or soon after weaning, from infectious diseases
and interactions of disease risk with poor nutrition (Wells
2009). Given that infectious disease risks, birth weight,
and early weight gain show high heritabilities (Demerath
et al. 2007; Kaslow et al. 2008; Beardsall et al. 2009), the
forces of natural selection and genetic response must pre-
sumably have impacted more strongly upon genetic vari-
ants favoring early-life survival (even into the early-fetal
stage) than upon virtually any other alleles or effects. A
primary implication of this simple inference is that extre-
mely strong, early selection can favor alleles that beneﬁt
early survival even if they engender substantial health and
ﬁtness costs later in life, owing to pleiotropy and linkage
disequilibrium.
This is well-established theory, but its implications have
yet to permeate the genetics of polygenic human disease.
Thus, studies of senescence and life history evolution have
focussed much more on laboratory demonstrations of
antagonistic pleiotropy, and deciphering physiological
mechanisms of age-related diseases, than on testing for
pleiotropic, age-speciﬁc effects from speciﬁc, health-
related alleles or developmental–physiological systems
(Rose 2009). Similarly, GWA studies of common diseases
sensibly compare cases and controls, for most diseases in
adults, to identify ‘risk’ alleles. To the extent, however,
that strong early-life effects and antagonistic pleiotropy
actually operate, many so-called disease-risk alleles, espe-
cially common ones like the APOE, ADRB2, and TP53
variants in Table 1 are expected to also be alleles ‘for’
phenotypes that confer higher survival or other beneﬁts
in childhood. Similar considerations apply to gene by
environment interactions, which may harbor much of the
‘missing’ heritability of polygenic disease (Manolio et al.
2009; Wermter et al. 2010); earlier environments, even
into the fetal stage, are expected to impose stronger
effects.
Several interesting implications follow from considering
the demographics of ancestral and current third-world
disease risks:
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on resisting infectious diseases, alleles that enhance early
infectious disease resistance should also frequently
increase risk from later-life noninfectious disease; such
processes may help to explain associations of HLA and
other immune loci with human longevity (e.g. Naumova
et al. 2007; Listı ` et al. 2010), and genetically-based trade-
offs between risks from infectious versus autoimmune
and late-life disease (Sanjeevi et al. 2000; Dean et al.
2002; Correa et al. 2005; Ferna ´ndez-Real and Pickup
2008; Van Bodegom et al. 2007; Mathieu et al. 2008;
Wang et al. 2010). Indeed, it is only among polygenic
autoimmune diseases such as rheumatoid arthritis and
type 1 diabetes that a substantial proportion of genetically
based disease liability has been accounted for (e.g.
Hakonarson and Grant 2009; Imboden 2009), perhaps
because of infectious diseases maintaining variation at the
immune-related loci that underly risk.
2) To the extent that early survival has historically
depended on relatively high birth weight, this phenotype
should engender late-life costs underlain by pleiotropic
alleles. For example, higher birth weight and large size
have been associated with increased risk of some forms of
cancer, at least in part because of alleles that enhance cell
proliferation (Cnattingius et al. 2009; Oberg et al. 2009;
Maehle et al. 2010). Similarly, the 8.1 ‘ancestral’ HLA
haplotype, found in about 10% of northern Europeans
and apparently subject to strong, ongoing positive selec-
tion (Aly et al. 2006), is associated with both higher birth
weight (Capittini et al. 2009) and increased risk from a
large suite of autoimmune and other disorders (e.g. Price
et al. 1999; Candore et al. 2002);
3) Under prenatal and early postnatal growth restriction,
offspring should be under strong selection to partition
available resources across different components of body
organ and tissue growth to even more directly maximize
early survival. Fetal ‘programming’ of adult disease was
discovered by David Barker in the context of spatial epi-
demiological associations of low infant survival and low
birth weight with increased rates of death from cardio-
vascular diseases and type 2 diabetes many years later
(Barker 1998). A simple hypothesis for helping to explain
this pattern involves a history of strong selection for
genetically based, environmentally induced growth alloca-
tion patterns (e.g. relative allocation to brain, vascular
system, insulin system function, immune function, etc.)
that maximize early postnatal survival under adverse pre-
natal conditions, at a cost in later-life reproduction and
survival. This hypothesis can help to explain genetically
based associations of low birth weight with type 2 diabe-
tes risk alleles (for the genes ADCY5, CDKAL1, GCK, and
HHEX-IDE; Weedon et al. 2006; Freathy et al. 2009,
2010; Zhao et al. 2010) where such alleles mediate varia-
tion in tradeoff structure, in the additional context of
birth weight beneﬁts to offspring from such T2D risk
alleles when present in the mother (Freathy et al. 2007,
2009; Lauenborg et al. 2009). Positive selection along the
human lineage has been reported on alleles of the T2D
risk genes TCF7L2 (Helgason et al. 2007), CDKAL1 (Teo
et al. 2009), and ALMS1 (Scheinfeldt et al. 2009), but the
relationships of selected versus ancestral alleles with rele-
vant phenotypes remain largely unexplored. Such genetic
effects are expected to be mediated in large part via con-
ditionally adaptive responses to environmental variation,
which involve epigenetic alterations that modify gene
expression and developmental phenotypes (e.g. Bruce and
Hanson 2010).
Compensatory childhood growth, which is known to
likewise engender late-life costs (e.g. Ong and Loos 2006),
should also be favoured by early-life selection under this
tradeoff framework, and transgenerational effects of early-
life adversity on birth weight and health (e.g. Kuzawa
2007; Kuzawa and Quinn 2009) may be explained in part
by selection on early survival that is generally stronger
than selection on investment in traits promoting female
fecundity, leading via both genetic and plasticity effects to
transgenerationally reduced investment in fecundity and
late-life health.
Strong selection for early-childhood survival in humans
may have important implications beyond genetically
based health risks: thus, early-childhood survival and
health have been strongly associated, in replicated studies
among traditional and other societies, with measures of
intelligence and education of the mother (Sandiford et al.
1997; Martin and Kubzansky 2005; Wachs et al. 2005;
C ˇvorovic ´ et al. 2008; Webb et al. 2010). Was the recent
evolution of brain development and intelligence in
humans driven by selection on mothers for cognitive,
affective, and behavioral phenotypes that enhance early-
childhood survival? In turn, how much of the precocial
neurological development of humans, coupled with physi-
cal altriciality, might be related to attracting early invest-
ment and health beneﬁts from the mother (e.g. Hrdy
1999)?
Tradeoffs are molecular genetic as well as phenotypic,
and uncovering the tradeoff structures of pleiotropic
alleles should provide novel insights into both human
evolution and disease risk
Tradeoffs between aspects of growth, maintenance, and
reproduction have most frequently been analyzed at the
levels of genetic and phenotypic correlations, but genetic
correlations must be underlain by pleiotropy and linkage
disequilibrium owing to genomic variation and molecu-
lar genetic mechanisms expressed in physiological and
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exhibit hierarchical structure, and causal connections,
from organisms to pathways to loci, at the following
levels:
1 whole-body, life history tradeoffs involve differential
allocation to growth, maintenance and reproduction, with
lifetime inclusive ﬁtness maximized under different
regimes of total available time and energy and strength of
tradeoffs (e.g. Jasienska 2009);
2 among-tissue tradeoffs involve differential growth of
organs during development, and differential allocation to
high-cost functions such as immunity and reproduction
in adulthood (e.g. Fig. 3), with the brain retaining a priv-
ileged position as master controller subject to high costs
from reduced allocation (Peters et al. 2004; Kuzawa 2010;
Straub et al. 2010);
3 within-tissue tradeoffs involve differential specialized
functions of speciﬁc tissues, such as fast-twitch versus
slow-twitch muscles (MacArthur et al. 2007; North 2008),
or brains relatively specialized for verbal versus visual-
spatial task performance (Johnson and Bouchard 2007);
4 within-pathway tradeoffs, whereby upregulation, for
example, of a growth-signaling pathway, enhances some
physiological–developmental functions but decreases oth-
ers, with consequent effects on disease risk in each case
(e.g. Caricasole et al. 2005; Reddy et al. 2009; Crespi
2010a); and
5 within-locus tradeoffs, whereby alternative genotypes
engender different sets of beneﬁts and costs; such trade-
offs should be mediated by mechanisms such as gene dos-
ages, enzyme activities, and afﬁnities for binding, and
should involve risks of different diseases.
Within-locus genetic variation provides some of the
best-known examples of molecular genetic tradeoffs, orig-
inally discovered because of their strong effects on disease
risks; thus, the HBB locus mediates tradeoffs between risk
of malaria and sickle-cell anemia, and TP53 mediates bal-
ances between reproduction, cancer, and senescence
(Kang et al. 2009). One of the most interesting aspects of
the data in Table 1 is that a substantial number of bal-
ancing selection cases involve losses of function for one
of the alleles; loss of function alleles are expected to arise
readily (given a larger set of mutational targets generating
null phenotypes than differently functional ones) but
increase disease risk because of deleterious effects in null
homozygotes (see also Barreiro and Quintana-Murci
2010). Of course, not all cases of balancing selection need
involve tradeoffs, as high allelic diversity can evolve for
other reasons, but the role of this process in maintaining
common alleles underlying disease risk deserves closer
scrutiny. Indeed, the Val158Met polymorphism of an
important schizophrenia-risk allele, COMT, has recently
been shown to be subject to balancing selection effects,
with heterozygotes demonstrating lower risk (Costas et al.
2010); do such effects generalize to other genes? Evidence
for beneﬁts from increased heterozygosity across many
loci has been reported with regard to heart disease
(Govindaraju et al. 2009); heterozygosity at a number of
speciﬁc non-HLA loci has been shown to enhance
survival of infectious or age-related disease (e.g. Kerlin
et al. 2003; Dossou-Yovo et al. 2007; Gochhait et al. 2007;
Hellemann et al. 2007; Catano et al. 2008; Livadas et al.
2009) and even low levels of inbreeding or homozygosity
from other causes in humans lead to elevated risks from
polygenic disease or death from infection (e.g. Lencz et al.
2007; Bacolod et al. 2008; Lyons et al. 2009a,b; Bittles and
Black 2010; Mansour et al. 2010). Indeed, on a larger
scale, increased homozygosity owing to founder effects in
dispersal from Africa appears to account for a higher inci-
dence of deleterious alleles in Europeans than Africans
(Lohmueller et al. 2008).
Under life history theory, tradeoffs can be alleviated in
part among a subset of individuals with high levels of ﬁt-
ness-enhancing resources (Reznick et al. 2000). With
regard to human disease, high heterozygosity, low levels of
de novo or rare deleterious, segregating mutations, high
levels of developmental resources, and benign environmen-
tal conditions (e.g. Gurven et al. 2009) may each reduce
the strength of tradeoffs involving components of ﬁtness
and disease risks. For example, tradeoffs between verbal
Figure 3 Storage and expenditure of resources for human growth,
maintenance, and reproduction involve tradeoffs at multiple levels,
from whole body to organs and tissues (shown here), and ultimately
to cells and alleles. Such tradeoffs are expected to structure the evolu-
tion, development and expression of polygenic disease risks, just as
they structure the evolution of human life history traits. From Wells
(2009), with permission.
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only after controlling for general intelligence (Ando et al.
2001; Johnson and Bouchard 2007), and a variety of neu-
rogenetic conditions, including Turner syndrome, Kline-
felter syndrome, and absence of the corpus callosum,
involve tradeoffs between this pair of cognitive phenotypes
(Brown and Paul 2000; Geschwind et al. 2000).
Conclusions
Evolutionary medicine represents one of the major con-
ceptual advances in the health sciences over the past
25 years (Gluckman et al. 2011), but its penetration into
the practice of medical research has been limited by: (i)
inherent difﬁculties in developing and testing evolutionary
hypotheses for human phenotypic adaptation and malad-
aptation, (ii) increasing specialization required for evolu-
tionary biologists to contribute within any given medical
research area, and (iii) ignorance and misunderstanding of
how evolutionary approaches can inform the study of
proximate mechanisms, and vice versa. These limitations
can be overcome relatively effectively by studying the joint
evolutionary genomic bases of human evolution and dis-
ease risk, which allows direct connections to be drawn
between selection, adaptation, and maladaptive traits.
Emergence of a robust, interdisciplinary human evolu-
tionary medical genomics will require integration of
human disease genetics with conceptual and analytic
approaches from evolutionary medicine, phylogenetics,
molecular genetics, life history theory, and study of the
genetic and phenotypic changes underlying modern
human origins. The most directly useful insights should
come from functionality of positively-selected and bal-
anced haplotypes and human-speciﬁc ﬁxed differences,
increased focus on mechanisms of genomic conﬂict and
their maladaptive sequelae, direct dovetailing of disease
risk and positive selection phenomic studies, and consid-
ering the genomic landscape of common polygenic dis-
ease as a spectrum of multi-level, timing-dependent and
tissue-dependent tradeoffs punctuated by deleterious
mutations. Indeed, under this perspective much, if not
most, of the common variants implicated thus far as dis-
ease risk alleles by GWAS may actually be beneﬁcial over-
all or in many contexts – to ﬁtness if not health. Human
disease risks have evolved, and the nascent ﬁeld of evolu-
tionary medical genomics offers unique and powerful
opportunities to bring proximate and ultimate approaches
together, for discovering how and why.
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